Remember Andrey Hicks? To recap, he’s the guy who was arrested last year (trying to make a run for Switzerland) and had his assets frozen by the Securities and Exchange Commission, which took issue with the fact that, in addition to stealing a couple million from investors in his Locust Offshore Management fund, he’d fed them a “brazen web of lies” that included: the claim he received a Ph.D in Applied Mathematics from Harvard in two years (he neither earned his doctorate from Harvard nor his undergraduate degree and in fact only lasted three semesters in Cambridge, taking a single math course, in which he got a D-); the claim that while working at Barclays Capital, he increased his group’s assets under management to $16 billion, despite BarCap having no record of his employment; the claim that at Locust, he applied “quantitative strategies based on mathematical models he developed at Harvard”; the claim that Ernst & Young was the fund’s auditor, Credit Suisse its prime broker and custodian, even though the SEC report was the first either had heard of the guy. Anyway, he’s probably going to spend some time in jail.
Corporate venture capital has begun to rival “traditional” venture capital and angel investing in its importance as an investment source for healthcare industry innovation. However, unlike VCs and angels, there is a dearth of information on how the various players in the corporate venture sector operate.